Table 5.
Clinical trials of mRNA vaccines targeting tumors associated viruses
| Cancer type | NCT number | Drug administration | Phase | Viruse | Status | Delivery system | Result | |
|---|---|---|---|---|---|---|---|---|
| Reproductive system tumors | cervical carcinoma | NCT06273553 | RG002 Injection (an mRNA Therapeutic Vaccine) | I | HPV16/18 | Not yet recruiting | Lipid nanoparticles | Not published |
| NCT02116920 | mRNA E6/E7 | I | HPV genotypes 16, 18, 31, 33 and 45 | Not yet recruiting | Lipid nanoparticles | Unknown | ||
| NCT05119855 | mRNA-1273 Vaccine | IV | 9-valent human papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) | Completed | Lipid nanoparticles | Not published | ||
| Skin tumor | Kaposi's sarcoma | NCT05217641 | BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA or BG505 MD39.3 gp151 CD4KO mRNA | I | HIV | Active,not recruiting | Lipid nanoparticles | Not published |
| NCT02413645 | TriMix 100, TriMix 300 | I | HIV | Completed | Lipid nanoparticles | The vaccine was secure and well tolerated. There were 31 grade 1/2 and 1 grade 3 adverse events, mostly unrelated to the vaccination. Patients who received the highest dose showed a moderate increase in T-cell responses spanning HTI sequence at week 8. In addition, the proportion of responders receiving any dose of HTI increased from 31% at w0 to 80% postvaccination. The intervention had no impact on caHIV-DNA levels, however, caHIV-RNA expression and usVL were transiently increased at weeks 5 and 6 in the highest dose of iHIVARNA, and these changes were positively correlated with HIV-1-specific-induced immune responses. | ||
| NCT00833781 | mRNA-transfected autologous dendritic cells | I | HIV | Completed | DC | There were no differences in interferon-gamma enzyme-linked immunospot responses to HIV-1 Gag or Nef in the vaccine or placebo group. CD4 proliferative responses to KLH increased 2.4-fold (P = 0.026) and CD8 proliferative responses to KLH increased 2.5-fold (P = 0.053) after vaccination. There were increases in CD4 proliferative responses to HIV-1 Gag (2.5-fold vs. baseline, 3.4-fold vs. placebo, P = 0.054) and HIV-1 Nef (2.3-fold vs. baseline, 6.3-fold vs. placebo, P = 0.009) among vaccine recipients, but these responses were short-lived. | ||
| Lymphatic system tumor | Burkitt's lymphoma | NCT05144748 | EBV mRNA vaccine | I | EBV | Recruiting | Lipid nanoparticles | Unknown |
| Digestive System Cancer | Hepatocellular carcinoma | NCT05738447 | HBV mRNA vaccine | I | HBV | Recruiting | Lipid nanoparticles | Unknown |